Abstract
Throughput in tuberculosis drug discovery was extremely limited prior to the introduction of microplate-based susceptibility assays. The 96-well Microplate Alamar Blue Assay (MABA) allows for the quantitative determination of drug susceptibility against any strain of replicating Mycobacterium tuberculosis to be completed within a week at minimal cost. The Low-Oxygen Recovery Assay (LORA) uses a recombinant M. tuberculosis expressing luciferase and provides results of drug activity against non-replicating M. tuberculosis surviving under hypoxic conditions. Determining activity against non-replicating M. tuberculosis is an important factor when developing drug candidates against M. tuberculosis. Here we describe a step-by-step procedure for both the MABA and LORA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
